The CCB Program Area has 24 core members, distributed among these three focus areas. During the current funding year, peer-reviewed funding totaled $12 million in total costs, including $1.45 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the CCB Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the CCB Program Area total $1,042,520. These funds supported Interdisciplinary Grants, Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared Resources and trainees. Twelve of the Program Area Members were the recipients of JCCC support. Cancer Cell Biology Program Area members published 201 peer-reviewed papers during the recent five-year renewal period. The JCCC CCB program area is highly interactive, with 9% of its 201 publications reflecting intraprogrammatic efforts and 59% reporting inter-programmatic collaborations. 129 publications (64%) appeared in high-impact journals. The Cancer Cell Biology (CCB) Program Area was previously named the """"""""Molecular, Cellular and Developmental Biology (MCDB) Program Area."""""""" In response to the 2002 CCSG review, and in extensive consultation with our External Advisory Board, the JCCC has reorganized this program. The goals of the reorganization were to: (1) identify critical cancer-relevant focus areas of basic science and biomedical technologies;(2) identify appropriate leaders and members for these focus areas;(3) promote intraprogrammatic interactions and collaborations within and across these groups in cancer-related areas;and (4) foster inter-programmatic interactions leading to translational and clinical collaboration. Concomitantly with the interest in reorganizing this program area, UCLA had made the strategic decision to invest heavily in infrastructure, faculty recruitment and funding in nanotechnology and stem cell biology;the California NanoSystems Institute and the Broad Stem Cell Center (BSCC) have both been created during the current JCCC CCSG funding cycle, and new buildings constructed to house these programs. The JCCC capitalized and incorporated the investment made by UCLA into our Program Area strategic plan and identified three main interest groups for the Cancer Cell Biology Program Area: (1) nanobiology applications to cancer detection, monitoring, and therapy;(2) cancer stem cell identification and eradication;and (3) model organism studies of cancer detection, progression, and therapy. Senior Associate Dean Dr. Leonard Rome, the former MCDB Program Area director, has become the JCCC Director for Strategic Planning and Partnerships. With the enthusiastic support of our EAB, Dr. Luisa Iruela-Arispe, an internationally known developmental biologist and cancer researcher has become the Director of the CCB Program Area. Dr. Michael Teitell, a pathologist and cancer biologist with strong interests in nanotechnology, brings strength in this area and a clinical perspective to the Co-Director position.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Wu, Sheng; Wong, Weng Kee; Crespi, Catherine M (2017) Maximin optimal designs for cluster randomized trials. Biometrics 73:916-926
Douaisi, Marc; Resop, Rachel S; Nagasawa, Maho et al. (2017) CD31, a Valuable Marker to Identify Early and Late Stages of T Cell Differentiation in the Human Thymus. J Immunol 198:2310-2319
Qi, Hangfei; Chu, Virginia; Wu, Nicholas C et al. (2017) Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein. Proc Natl Acad Sci U S A 114:2018-2023
Lu, Jianqin; Liu, Xiangsheng; Liao, Yu-Pei et al. (2017) Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun 8:1811
Castaneda, Julie T; Harui, Airi; Roth, Michael D (2017) Regulation of Cell Surface CB2 Receptor during Human B Cell Activation and Differentiation. J Neuroimmune Pharmacol 12:544-554
Casillas, Jacqueline; Goyal, Anju; Bryman, Jason et al. (2017) Development of a text messaging system to improve receipt of survivorship care in adolescent and young adult survivors of childhood cancer. J Cancer Surviv 11:505-516
Su, Yapeng; Wei, Wei; Robert, Lidia et al. (2017) Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. Proc Natl Acad Sci U S A 114:13679-13684
Demer, Linda L; Tintut, Yin; Nguyen, Kim-Lien et al. (2017) Rigor and Reproducibility in Analysis of Vascular Calcification. Circ Res 120:1240-1242
Kiyohara, M H; Dillard, C; Tsui, J et al. (2017) EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene 36:5793-5807
Dock, Jeffrey; Ramirez, Christina M; Hultin, Lance et al. (2017) Distinct aging profiles of CD8+ T cells in blood versus gastrointestinal mucosal compartments. PLoS One 12:e0182498

Showing the most recent 10 out of 721 publications